Functional mismatch repair and inactive p53 drive sensitization of colorectal cancer cells to irinotecan via the IAP antagonist BV6
Sign Up to like & getrecommendations! Published in 2019 at "Archives of Toxicology"
DOI: 10.1007/s00204-019-02513-7
Abstract: A common strategy to overcome acquired chemotherapy resistance is the combination of a specific anticancer drug (e.g., topoisomerase I inhibitor irinotecan) together with a putative sensitizer. The purpose of this study was to analyze the… read more here.
Keywords: cells irinotecan; bv6; p53; mismatch repair ... See more keywords
The IAP Antagonist Debio 1143 Enhances Chemoradiotherapy in HNSCC.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2020-116
Abstract: Debio 1143 plus chemoradiotherapy improved head and neck squamous cell carcinoma disease control. read more here.
Keywords: antagonist debio; 1143 enhances; debio; chemoradiotherapy ... See more keywords
Lipopolysaccharide sensitizes the therapeutic response of breast cancer to IAP antagonist
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.906357
Abstract: Inhibitor of apoptosis protein (IAP) is a class of E3 ubiquitin ligases functioning to support cancer survival and growth. Many small-molecule IAP antagonists have been developed, aiming to degrade IAP proteins to kill cancer. We… read more here.
Keywords: breast cancer; apoptosis; cancer; iap antagonist ... See more keywords